Harpoon Therapeutics Inc (NASDAQ:HARP), presented interim data from the ongoing dose-escalation portion of a Phase 1 trial for HPN424 in patients with metastatic castration-resistant prostate cancer (mCRPC).
According to Harpoon, the initial safety data from the 44-patient trial showed that HPN424 is generally well-tolerated and cytokine-related adverse events have been transient and manageable.
Pharmacokinetic data supports weekly dosing and pharmacodynamic data supports T cell activation and target engagement consistent with the expected mechanism of action.
Autolus Therapeutics PLC ( (NASDAQ: AUTL) announced new data highlighting progress on AUTO3, a CAR T cell therapy being investigated in a Phase 1/2 study in relapsed/refractory diffuse large B cell lymphoma (DLBCL).
According to Autolus, the data continues to show encouraging clinical activity alongside tolerable safety to deliver a potentially highly differentiated product profile
AUTO3 was well tolerated, with no patients experiencing dose-limiting toxicity, and there were no treatment-related deaths.
Arix has a 6.45% stake in Autolus and 10.4% in Harpoon.